Gloria Ravegnini, Bruno Fosso, Riccardo Ricci, Francesca Gorini, Silvia Turroni, Cesar Serrano, Daniel F. Pilco‐Janeta, Qianqian Zhang, Federica Zanotti, Mariangela De Robertis, Margherita Nannini, Maria Abbondanza Pantaleo, Patrizia Hrelia, Sabrina Angelini, Institut Català de la Salut, [Ravegnini G, Gorini F, Turroni S] Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy. [Fosso B] Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council, Bari, Italy. Department of Biosciences, Biotechnology and Biopharmaceutics (DBBB), University of Bari 'A. Moro', Bari, Italy. [Ricci R] Department of Pathology, Catholic University, Rome, Italy. [Serrano C] Laboratori de Recerca Translacional de Sarcoma, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pilco-Janeta DF] Laboratori de Recerca Translacional de Sarcoma, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA, Vall d'Hebron Barcelona Hospital Campus, Ravegnini, Gloria, Fosso, Bruno, Ricci, Riccardo, Gorini, Francesca, Turroni, Silvia, Serrano, Cesar, Pilco-Janeta, Daniel F., Zhang, Qianqian, Zanotti, Federica, De Robertis, Mariangela, Nannini, Margherita, Pantaleo, Maria Abbondanza, Hrelia, Patrizia, and Angelini, Sabrina
Carcinogenesis; Microbiome; Tumor evolution Carcinogènesi; Microbioma; Evolució del tumor Carcinogénesis; Microbioma; Evolución del tumor Preclinical forms of gastrointestinal stromal tumor (GIST), small asymptomatic lesions, called microGIST, are detected in approximately 30% of the general population. Gastrointestinal stromal tumor driver mutation can be already detected in microGISTs, even if they do not progress into malignant cancer; these mutations are necessary, but insufficient events to foster tumor progression. Here we profiled the tissue microbiota of 60 gastrointestinal specimens in three different patient cohorts—micro, low-risk, and high-risk or metastatic GIST—exploring the compositional structure, predicted function, and microbial networks, with the aim of providing a complete overview of microbial ecology in GIST and its preclinical form. Comparing microGISTs and GISTs, both weighted and unweighted UniFrac and Bray–Curtis dissimilarities showed significant community-level separation between them and a pronounced difference in Proteobacteria, Firmicutes, and Bacteroidota was observed. Through the LEfSe tool, potential microbial biomarkers associated with a specific type of lesion were identified. In particular, GIST samples were significantly enriched in the phylum Proteobacteria compared to microGISTs. Several pathways involved in sugar metabolism were also highlighted in GISTs; this was expected as cancer usually displays high aerobic glycolysis in place of oxidative phosphorylation and rise of glucose flux to promote anabolic request. Our results highlight that specific differences do exist in the tissue microbiome community between GIST and benign lesions and that microbiome restructuration can drive the carcinogenesis process. Francesca Goriini and Federica Zanotti have been supported by Fondazione Cassa di Risparmio di Bologna.